We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Benchmark Holdings Plc | LSE:BMK | London | Ordinary Share | GB00BGHPT808 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -1.10% | 45.00 | 44.10 | 45.90 | 43.20 | 43.00 | 43.00 | 126,760 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 169.74M | -23.15M | -0.0313 | -13.80 | 319.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/7/2016 07:22 | Great RNS - strong IP and Euro 300m market potentially and more is vaccine is developed for other farmed fish species RNS Number : 5178E Benchmark Holdings PLC 19 July 2016 Benchmark's new seabass vaccine commences commercial field trials Benchmark is pleased to announce that one of its new generation aquaculture vaccines has been released into the market for commercial field trials. The vaccine is the first in a series of Benchmark's new vaccines targeted at the €300m Mediterranean seabass market and aims to provide producers with an effective control of Nodavirus - a disease that impedes growth and causes high production losses. There was previously no effective treatment available for this endemic disease. The trials will see a significant number of leading producers use the new vaccine 'on-farm' at commercial scale ahead of market authorisation, a process which typically takes 9 to 12 months. Full development of the product has been undertaken in-house through exploiting the Group's R&D expertise, vaccine manufacturing capability and aquaculture trials facilities to ensure a streamlined and secure development process. Nodavirus also affects several other farmed aquaculture species including Turbot, Barramundi and Grouper, and Benchmark now plans to provide these sectors with a similar solution. The development process for producing this vaccine for seabass can now be readily adapted to bring forward vaccines for these other species. Malcolm Pye, Benchmark's CEO commented: "This is another key milestone for Benchmark and is testament to our increased capability, as we continue to invest in our manufacturing capacity and technology, to open up new markets for the company by solving major challenges for our customers. This product represents a significant first for the Company, as the full development process including research, design, development and manufacturing, has been delivered entirely in-house by our specialist teams." | multibagger | |
15/7/2016 18:17 | Yeah strong sign of confidence - could be a inter-fund trade. I recall some big trades around the 22nd of June as well that I commented on either on this thread or on LSE. (Edit: 24m approx traded in big deals on that day) Re the Equity Development presentation..... The most interesting part for me was the pipeline and stages at which various products were in development. I particularly like the business model and the way that the divisions interlink synergestically. The Directors have decent skin in the game and I think that the move into tilapia and shrimp will generate a lot of revenue from the developing economies. Apart from all this, the current market price offers a good margin of safety compared to placing price. I have taken a little over 154k shares so far and intend to hold for a minimum of 3-5 years for starters. This time frame is likely to be transformational and I would not rule out the possibility of a takeover by a food giant at a good premium to where we are now. Good luck all :) | multibagger | |
15/7/2016 14:50 | Someone just bought over £400k worth. | mad foetus | |
15/7/2016 12:01 | 33% increase in salmon prices over the 12 weeks....good for us :) hxxps://salmonprice. Added another 18k this morning - though at a premium today still at a significant discount to the 85-86p placement not too long ago. Good luck all :) | multibagger | |
15/7/2016 11:50 | Sudden bit of activity here.Take a look at GWMO too for tenbagger potential from £1m market cap.Build a position now, before the crowds arrive | apfindley | |
08/7/2016 13:59 | A recording of the recent webinar with the management of Benchmark is now available to view at: Thanks, The Equity Development team | hannahh | |
03/7/2016 09:23 | Look out for rising fish prices. A mixture of environmental issues – toxic algae bloom in Chile, an outbreak of lice in Norway, cold weather restricting growth – has resulted in a major shortage of salmon. From the Guardian, today | mad foetus | |
23/6/2016 20:39 | Agree, nice buy at 68p, looks like we will get a good run up prior to results. Still well under the radar, could easily pop. | mad foetus | |
23/6/2016 19:43 | Good size transactions persisting and price moving upwards nicely :) | multibagger | |
22/6/2016 13:58 | Shuffling between institutions or new insti coming on board. May trigger a RNS by end of play. Woodford has been trimming various positions according to posters on TRX thread. | multibagger | |
22/6/2016 13:53 | 24m volume. hmm, something going on. | mad foetus | |
22/6/2016 13:33 | Interesting trades | che7win | |
20/6/2016 10:48 | results next Tuesday, chart looking quite tasty. of course, referendum could scupper the market but a weaker pound would help BMK. | mad foetus | |
10/6/2016 13:39 | Well most of the recent institutional placing was at 85/86p ? ...so definite margin of safety at this price.So not sure who they would be letting out at this level ? I am buying with a 3-5 year time frame for starters...they have a sound strategy with regards to acquisitions. I am pretty confident that the integration will occur reasonably smoothly. The equity free float is small (the company website says 76.85% is not in public hands), so any demand post results or at any point, can move this apace. I think the market is mispricing the value of the Inve deal and not factoring in the transformational nature of the same. BMK are putting together a great company and would be ripe for a takeover in due course by the likes of one of the agri majors like Bayer, Monsanto etc. | multibagger | |
10/6/2016 12:53 | or maybe they are letting someone out? | mr roper | |
10/6/2016 08:36 | My/family ISA accounts are with HL and they are not as good in filling the orders in my experience. Self trade is not very good either from experience. | multibagger | |
10/6/2016 08:31 | thanks, multi. mf, definitely looks like something is going on behind the scenes.. | mr roper | |
10/6/2016 08:30 | Hmm, trades are going through above the ask - they are trying to keep a lid on this imo to allow a few more of their clients into the ground before the game kicks off. | mad foetus | |
10/6/2016 08:27 | Hi Mr Roper, This trade was through Halifax online..about 10-12 min ago... | multibagger | |
10/6/2016 08:24 | who did you go through for your order, multibagger? I'm with HL and get a fill for 10k! Reckon it's gonna pop. | mr roper | |
10/6/2016 08:19 | Added another 30k @66.5 Loads of value to play for.... | multibagger | |
10/6/2016 08:08 | get up there | abarclay | |
09/6/2016 16:32 | This is undergoing a rerating, I expect continuing upwards movement. | che7win |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions